Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

to $1.00 per share which may be paid upon the achievement of certain regulatory and commercial milestones. The first CVR payment of $0.50 per share (or $87.5 million) would become payable when either (i) Cinryze is approved by the FDA for acute treatment of HAE and the FDA grants orphan exclusivity for Cinryze encompassing the acute treatment of HAE to the exclusion of all other human C1 inhibitor products or, (ii) orphan exclusivity for the acute treatment of HAE has not become effective for any third party's human C1 inhibitor product by October 21, 2010. The second CVR payment of $0.50 per share ($87.5 million) would become payable when Cinryze reaches at least $600 million in cumulative net product sales within 10 years of closing of the acquisition.

Looking ahead in 2009

ViroPharma is providing guidance for the year 2009 as a convenience to investors. The following guidance provided by ViroPharma are projections, based upon numerous assumptions, all of which are subject to certain risks and uncertainties. For a discussion of the risks and uncertainties associated with these forward looking statements, please see the Disclosure Notice below.

For the year 2009, ViroPharma expects the following

  • Net product sales are expected to be $250 to $270 million. This guidance assumes no generic versions of Vancocin are approved in 2009 and excludes any revenue guidance for Cinryze.

  • Research and development (R&D) and selling, general and administrative (SG&A) expenses, including the impact of SFAS 123R, are expected to be $130 to $145 million, which includes approximately $25 million of expenses and previous commitments related to maribavir. SFAS 123R expenses are expected to be between $11 and $13 million.

Conference Call and Webca
'/>"/>

SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... (PRWEB) August 28, 2014 The ability ... a culture that will allow individuals to perform at ... increasingly important for employers looking to compete in this ... are embracing this trend, as the sector increasingly focuses ... a company, which will have real results on the ...
(Date:8/28/2014)... -- Next month, executives from clinical trial marketing firm BBK Worldwide ... Patient-Centered Clinical Trials 2014 , to be held at ... September 4-5. Patient recruitment experts Bonnie A. Brescia , ... share insights on the benefits of employing an effective patient ... media to mobile apps – can be used to drive ...
(Date:8/28/2014)... 2014   SunTrust Robinson Humphrey (STRH) ... to its equity research team in biotechnology and ... in equity research demonstrates our commitment to providing ... enhance their investment decision making," said Biff ... continue to make significant investments in differentiated content ...
(Date:8/28/2014)... Sterlitech is proud to announce that it is ... of products . These additional products increase the ... filters with surface charges. , “We have ... membrane process testing equipment, and correspondingly, a wider demand ... Sterlitech President Mark Spatz. “The addition of Synder ...
Breaking Biology Technology:Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3BBK Worldwide Leads Sessions at Key September Events 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3Sterlitech Corporation Enhances Its Selection of Flat Sheet Membrane Filters 2
... , CHICAGO , May 26 ... Board: ADLS), a biopharmaceutical company engaged in the discovery, development ... infection, oncology and respiratory diseases, today announced positive results from ... assessing the efficacy of Restanza™ (cethromycin), its novel oral antibiotic, ...
... ... At the beginning of 2010, MIND360.com launched a two month ... brain training games as a creative and fun way to improve ... perception. The pilot was declared a success, showing an improvement the ...
... how they behave could help scientists to grow cells that ... Edinburgh has shown that embryonic stem cells consist of cells ... types. This may be linked to their potential to become ... help scientists catch embryonic stem cells at exactly the right ...
Cached Biology Technology:Advanced Life Sciences Announces Restanza(TM) Shows Efficacy Against Malaria 2Advanced Life Sciences Announces Restanza(TM) Shows Efficacy Against Malaria 3Advanced Life Sciences Announces Restanza(TM) Shows Efficacy Against Malaria 4Advanced Life Sciences Announces Restanza(TM) Shows Efficacy Against Malaria 5High School Brain Training - A Successful Pilot 2High School Brain Training - A Successful Pilot 3Study sheds light into the nature of embryonic stem cells 2
(Date:8/28/2014)... good examples of complex systems. Their infrastructure equipment ... for cooling, transport to supply fuel, and ICT ... the network chain is interconnected with a wider ... team of UK-based scientists has studied various aspects ... have been published in EPJ B by Gaihua ...
(Date:8/28/2014)... Aug. 28, 2014A new method for measuring and imaging ... doctors and researchers better understand how drug abuse affects ... and tissue engineering, and lead to better treatment options ... a team of researchers from Stony Brook University in ... Health, was published today in The Optical Society,s (OSA) ...
(Date:8/28/2014)... Dyslexia, the most commonly diagnosed learning disability ... disability that occurs when the regions of the ... , The use of non-invasive functional neuroimaging tools ... in dyslexia. However, most prior work has focused ... leaving a gap in our understanding of how ...
Breaking Biology News(10 mins):Inter-dependent networks stress test 2This is your brain's blood vessels on drugs 2This is your brain's blood vessels on drugs 3Dyslexic readers have disrupted network connections in the brain 2
... to low levels of an asbestos-like mineral from Montana ... risk for lung disease today, according to research from ... is a mineral with a flaky, fluffy-looking structure. Previous ... Mont., contained increased levels of an asbestos-like mineral fiber ...
... has on learning in ground squirrels could have an ... to a University of Chicago researcher. Jill Mateo, ... when they perform normal survival tasks, ground squirrels learn ... cortisol, a hormone produced in response to stress, than ...
... examples of creatures that try to look as big as ... to avoid being eaten alive the larvae of sand dollars ... a dollar for a couple of dimes. University of ... clones of themselves within 24 hours of being exposed to ...
Cached Biology News:Low exposure to asbestos-like mineral from Montana vermiculite may up lung disease risk 2Research with squirrels provides clues on hormone's role in human learning 2Sand dollar larvae use cloning to 'make change,' confound predators 2Sand dollar larvae use cloning to 'make change,' confound predators 3